e-learning
resources
2019
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia
Pouline M. van Oort, Lieuwe D. Bos, Pedro Póvoa, Paula Ramirez, Antoni Torres, Antonio Artigas, Marcus J. Schultz, Ignacio Martin-Loeches
Source:
ERJ Open Res, 5 (1) 00212-2018; 10.1183/23120541.00212-2018
Journal Issue:
February
Disease area:
Respiratory critical care, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Pouline M. van Oort, Lieuwe D. Bos, Pedro Póvoa, Paula Ramirez, Antoni Torres, Antonio Artigas, Marcus J. Schultz, Ignacio Martin-Loeches. Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia. ERJ Open Res, 5 (1) 00212-2018; 10.1183/23120541.00212-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Soluble urokinase plasminogen activator receptor (suPAR) for the prediction of ventilator-associated pneumonia (VAP)
Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Year: 2018
Soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in exacerbated COPD
Source: International Congress 2018 – New predictors of morbidity and mortality in COPD
Year: 2018
Soluble urokinase plasminogen activator receptor (suPAR) is associated with COPD readmission and mortality
Source: International Congress 2019 – Long-term lung function: from early birth to adulthood
Year: 2019
Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma
Source: Eur Respir J 2016; 47:1568-1571
Year: 2016
Enoxaparin reduced ventilation-induced plasminogen activator inhibitor-1
Source: Annual Congress 2009 - Crossing the line: alveolo-capillary barrier control in acute lung injury
Year: 2009
Upregulation of the gene encoding the urokinase-type plasminogen activator (uPA) in respiratory muscles of COPD patients
Source: Annual Congress 2004 - Skeletal muscle in respiratory disease
Year: 2004
Soluble urokinase plasminogen activator receptor (suPAR) predicts hospital readmissions and all-cause mortality in patients admitted with asthma
Source: International Congress 2019 – Long-term lung function: from early birth to adulthood
Year: 2019
Soluble urokinase-type plasminogen activator receptor in monitoring of treatment response in acute exacerbation of chronic obstructive pulmonary disease
Source: International Congress 2017 – Current challenges in COPD evaluation
Year: 2017
The relation between plasminogen activator inhibitor-1 (PAI-1) and inflammatory markers in COPD: A possible risk factor of inflammation-induced thrombosis
Source: International Congress 2017 – Systemic and airway biomarkers
Year: 2017
Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis
Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis
Year: 2010
LATE-BREAKING ABSTRACT: Molecular mechanisms of plasminogen activator inhibitor-1 elevation in COPD sputum
Source: Annual Congress 2012 - Cell biology and inflammatory gene expression in chronic lung disease
Year: 2012
Pro-urokinase up-regulates the expression of urokinase type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells
Source: Eur Respir J 2007; 30: Suppl. 51, 143s
Year: 2007
The regulation of plasminogen activator inhibitor-1 (PAI-1) production with dexamethasone by human lung fibroblasts
Source: Eur Respir J 2005; 26: Suppl. 49, 343s
Year: 2005
Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD
Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease
Year: 2015
Half - dose of recombinant tissue-type plasminogen activator in the treatment of acute pulmonary embolism: long term outcomes
Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism
Year: 2017
Urokinase type plasminogen activator improves airway inflammation and mucin expression in a murine asthma model
Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung
Year: 2010
Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection
Source: ERJ Open Res, 5 (3) 00084-2019; 10.1183/23120541.00084-2019
Year: 2019
The effect of prostaglandin (PG) E2 and its receptor antagonists on urokinase-type plasminogen activator (uPA) production by human lung fibroblasts
Source: Eur Respir J 2006; 28: Suppl. 50, 811s
Year: 2006
Outcomes of intrapleural tissue plasminogen activator (tPA) and deoxyribnuclease (DNase) for IPC-related pleural infection
Source: International Congress 2019 – Pleural infection and complicated pneumonia
Year: 2019
Prognostic value of urokinase plasminogen activator receptor (uPAR) and neutrophil CD64 expression in acute respiratory distress syndrome patients
Source: Annual Congress 2013 –Acute respiratory failure, ARDS and severe COPD exacerbations
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept